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Abstract
Adjuvant formulations capable of inducing high titer and high affinity antibody responses would provide a major advance
in the development of vaccines to viral infections such as HIV-1. Although oil-in-water emulsions, such as Freund’s adjuvant
(FCA/FIA), are known to be potent, their toxicity and reactogenicity make them unacceptable for human use. Here, we
explored different adjuvants and compared their ability to elicit antibody responses to FCA/FIA. Recombinant soluble
trimeric HIV-1 gp140 antigen was formulated in different adjuvants, including FCA/FIA, Carbopol-971P, Carbopol-974P and
the licensed adjuvant MF59, or combinations of MF59 and Carbopol. The antigen-adjuvant formulation was administered in
a prime-boost regimen into rabbits, and elicitation of antigen binding and neutralizing antibodies (nAbs) was evaluated.
When used individually, only FCA/FIA elicited significantly higher titer of nAbs than the control group (gp140 in PBS
(p,0.05)). Sequential prime-boost immunizations with different adjuvants did not offer improvements over the use of FCA/
FIA or MF59. Remarkably however, the concurrent use of the combination of Carbopol-971P and MF59 induced potent
adjuvant activity with significantly higher titer nAbs than FCA/FIA (p,0.05). This combination was not associated with any
obvious local or systemic adverse effects. Antibody competition indicated that the majority of the neutralizing activities
were directed to the CD4 binding site (CD4bs). Increased antibody titers to the gp41 membrane proximal external region
(MPER) and gp120 V3 were detected when the more potent adjuvants were used. These data reveal that the combination of
Carbopol-971P and MF59 is unusually potent for eliciting nAbs to a variety of HIV-1 nAb epitopes.
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Introduction
One of the major challenges in developing vaccines against
highly variable viruses, such as HIV-1 and HCV, is the relatively
poor immunogenicity of the subunit Envelope glycoprotein (Env)
antigens, which fail to elicit antibody responses that protect against
the majority of circulating viral strains. Early studies on HIV-1
indicated an inverse correlation between antibody binding avidity
and the frequency of transmission [1,2,3]. In order to generate
high avidity antibodies, antigen-activated B cells need to undergo
extensive somatic hypermutation. It has been demonstrated during
the immune response to HIV-1 infection, that somatic hypermu-
tation is essential to increase antibody affinity and neutralization
breadth and potency [4]. Indeed, analyses on some of the broadly
neutralizing antibodies (bnAbs) against HIV-1 reveal that these
bnAbs undergo 19–46% more somatic hypermutation than their
weakly or non-neutralizing counterparts [5,6,7,8,9,10]. Given
these observations, an ideal vaccine should, therefore, include an
adjuvant that can drive somatic hypermutation, in the hope of
eliciting high avidity antibodies with increased breadth and
potency.
Adjvuants are substances capable of stimulating an immune
response to an antigen. Due to their immunopotentiating and
immunostimulatory properties, adjuvants can greatly reduce the
dose and number of immunizations required to achieve sustained
protective immunity [11,12,13,14,15,16], which is of particular
importance during pandemic outbreaks. A central issue in
developing an adjuvant suitable for clinical use is possible risk of
local and systemic reactogenicity and toxicity. For example,
Freund’s complete adjuvant (FCA), which is a paraffin oil-in-water
emulsion containing heat-inactivated bacterial products (M.
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tuberculosis or M. butryicum), is known to be very potent and is often
used for generation of high titer antisera in animals [17]. However
FCA is toxic and causes cell and tissue damage upon injection. To
reduce toxicity, bacterial components were removed in related oil-
in-water adjuvants, such as Freund’s incomplete adjuvant (FIA)
and Montanide ISA [18,19]. Immunization of malarial or HIV-1
antigens in Montanide ISA induced both nAbs and CD8+ T-cell
responses [20,21,22,23]. However, a number of vaccinees in these
studies developed prolonged pain and sterile abscess formation at
the injection site or experienced severe systemic reactions,
suggesting that the adjuvant is not suitable for use in human
vaccines [20,21,22,23].
Because of their respectable safety record, aluminum-based salts
(alums) remain the dominant adjuvants allowed for human use
since their initial successful formulation for tetanus toxin vaccine
[24]. However, alum is only weakly stimulatory especially when
compared to FCA/FIA [25], and since part of its function is to
precipitate antigen, this may adversely affect the antigenicity of
conformationally-sensitive antigens. Hence, substantial efforts
have been devoted in recent years to developing a new generation
of potent and safe adjuvants. It was not until 1997 that MF59 was
licensed for use in the seasonal influenza vaccine for the elderly in
Europe, the first new adjuvant licensed since alum [26]. MF59 is a
squalene oil-in-water emulsion stabilized by Tween-80 and Span
85 surfactants [26,27]. It was found to cause significant local
immune stimulation and recruit and increase antigen uptake by
dendritic cells (DCs) [28,29,30]. Early studies in baboons and
humans showed that MF59 offered superior potency over alum
with an HBV vaccine [31,32]. Subsequent clinical trials with
CMV, HSV and HIV-1 candidate vaccines indicated that MF59
was well tolerated in human volunteers including infants, and
enhanced humoral as well as T-helper responses [33,34,35,36,37].
In addition to oil-in-water emulsions, many other types of
experimental adjuvant are under intensive evaluation, including
synthetic polymers. Polyanionic carbomers, such as Carbopols,
have long been used in pharmaceuticals as controlled release
agents for oral tablets or as bioadhesives for topical or trans-
mucosal drug delivery [38,39]. Pilot studies of experimental
veterinary vaccines with different types of Carbopol adjuvant have
shown increased antibody responses with low reactogenicity
[40,41], and one of the carbomers, Carbopol-941P, is licensed
for vaccine use in pigs (Suvaxyn, Pfizer) [42,43]. The adjuvanticity
of two other polyanionic carbomers, Carbopol-971P and Carbo-
pol-974P, was recently analyzed by others [44,45]. Both polymers
are networks of primary polyacrylic acid chains interconnected by
crosslinks. The 971P formulation has lower viscosity and fewer
crosslinking sites than the 974P formulation [46,47].
Here, we compare a number of adjuvants, including FCA/FIA,
MF59, Carbopol-971P and 974P in the context of soluble
recombinant HIV-1 gp140 antigen, by systemic immunization of
rabbits. Based on our findings, we propose that specific adjuvant
combinations drive antibody responses more effectively than using
adjuvants singly.
Materials and Methods
Ethics statement
The animal study was carried out in strict accordance with the
UK Animals (Scientific Procedure) Act 1986, and the protocol was
approved by the local Ethical and Welfare Committee of the
University of Cambridge and the UK Home Office (Project license
no. 80/2238).
Recombinant gp140 purification
HIV-1 gp140SF162 has been previously characterized and was
obtained as culture supernatant from Novartis Vaccines &
Diagnostics, USA. The gp140 glycoprotein was purified using a
published protocol [48]. Briefly, supernatant was loaded onto a
Galanthus nivalis agarose affinity column equilibrated with buffer
(20 mM Tris, 100 mM NaCl, pH 7.4), and bound gp140 was
eluted with 500 mM methyl mannose pyranoside in equilibration
buffer. The eluate was then loaded onto a DEAE column
equilibrated with buffer (20 mM Tris, 100 mM NaCl, pH 8.0),
such that contaminants were bound to the column while the gp140
flowed through. The flow-through was adjusted to pH 6.8 with
10 mM NaPO4 before loading onto a ceramic hydroxyapatite
(CHAP) column that has been previously equilibrated with buffer
(10 mM Na2HPO4, 100 mM NaCl, pH 6.8). The flow through,
which contained the purified glycoprotein, was collected and then
concentrated to 1 mg/ml using an AMICON YM-30 (30 kDa cut-
off) ultrafiltration disc (Millipore, UK) and stored at 280uC until
use.
Adjuvant-immunogen formulation
The gp140SF162 (25 mg per animal) was formulated with
different adjuvant(s) immediately prior to immunization. A
detailed example on the dosages for each adjuvants and antigen
is shown in Table S1. In order to keep the final volume identical in
all groups, 25 mg of gp140SF162 (1 mg/ml) was first diluted 1:1 (v/v)
with PBS, or 25 ml glycoprotein to 25 ml of PBS, before mixing 1:1
(v/v) with Freund’s complete or incomplete adjuvant (Sigma-
Aldrich, UK), or MF59 (Novartis Vaccines & Diagnostics, USA).
The mixture, with a final volume of 100 ml (per animal), was then
incubated for 10 min before injection. For Carbopol-971P
(Lubrizol, USA) and 974P (Particle Sciences, USA), both polymers
were first prepared to a 2% (w/v) suspension with enough PBS,
before mixing 1:1 (v/v), or 25 ml to 25 ml, with gp140SF162. The
mixture was then brought to the same final volume of 100 ml with
PBS and incubated for 30 min before injection [44,45]. For the
combination groups, gp140 was first mixed 1:1 (v/v), or 25 ml to
25 ml, with 2% Carbopol-971P/974P and incubated for 30 min.
The mixture was then added 1:1 (v/v) with 50 ml of MF59 and
incubated for another 10 min before injection. For the no
adjuvant group, 75 ml of PBS was added to gp140SF162 (25 ml) to
make the final volume 100 ml for the injection. Due to the high
viscosity of the adjuvants, substantial vortexing was required
during the formulation process to ensure the antigen-adjuvant
mixture was homogenized before use.
Protein gel electrophoresis
The conformation of the gp140, in the presence or absence of
adjuvants, was assessed by reducing, non-reducing and Blue-
Native (BN) polyacrylamide gel electrophoresis using standard
protocols. Briefly, gp140SF162 was formulated with or without
adjuvant(s) as described above. To separate the glycoprotein from
the adjuvant(s), the mixture was centrifuged at high speed for
30 min and the aqueous phase, which contained the glycoprotein,
was extracted and quantified with a spectrophotometer. The
extracted glycoprotein was then denatured at 90uC and reduced
with beta-mercaptoethanol (bME) for reducing SDS-PAGE. The
glycoproteins were not heat denatured or treated with bME for the
non-reducing condition. Coomassie Blue dye was added to 5 mg of
gp140 and then separated in the absence of sodium dodecyl
sulphate for BN-PAGE.
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Antibody binding assay
The effect of adjuvant on antigenicity was also analyzed by
antibody binding. Briefly, gp140SF162 was first formulated with
adjuvant(s) and then extracted before being coated (0.5 mg/well) to
microwell plates for 2 h at 16uC. The plates were washed 3 times
with 16 PBS and blocked with 5% BSA for 30 min, followed by
another 3 washes with PBS. Monoclonal antibodies labeled with
Europium (Perkin Elmer, UK) were added (100 ng/well) and
incubated for 1 h at 16uC. The plates were washed 3 times with
wash buffer (25 mM Tris-HCl pH 7.8 containing 1% Triton X-
100). Enhancement solution (200 ml/well; Perkin Elmer) was
added and the plates were developed for 15 min and the Relative
Luminescence Unit (RLU) emitted were measured with a 1420
Victor Multilabel Counter (Perkin Elmer, UK).
Immunization and sera collection
Twelve groups of 6 New Zealand white female rabbits each
received 3 intramuscular immunizations of gp140SF162 at week 0,
4 and 12 (Figure S1). Except for animals in group 1, in which
75 mg/injection of gp140 was used, all other animals received
25 mg of gp140 for each immunization. Animals in both groups 1
and 2 received FCA for the first immunization and FIA for the
next two. Animals in groups 3–5 received MF59, Carbopol-971
or, Carbopol-974P for all three injections, respectively. For groups
6 and 7, rabbits received either Carbopol-971P or Carbopol-974P
for the first injection, followed by MF59 for the next two. The
regimen was reversed for groups 8 and 9, in which animals were
injected twice with MF59, followed by a final injection of either
Carbopol-971P or Carbopol-974P. For group 10, animals received
a mixture of Carbopol-971P and MF59 adjuvants for all three
immunizations. Similarly, animals in group 11 received a mixture
of Carbopol-974P and MF59 for all three immunizations. Finally,
animals in group 12 received only gp140SF162 for all three
injections, without any adjuvant. Serum samples were collected 2
weeks before and after each immunization at week 22, 2, 6 and
14, and a terminal sample was collected at week 16. One of the
animals in group 1 died before the end of the study of cause
unrelated to adjuvant toxicity.
Endpoint titer and avidity index ELISA
The endpoint titers of Env-specific antibodies in the sera were
measured by standard ELISA. Briefly, 96 maxisorp microwell
plates (Nunc, UK) were coated overnight with purified gp140SF162
(50 ng/well) in 50 mM sodium carbonate-bicarbonate buffer
(pH 9.6) at 4uC, and then blocked with PBS containing 0.05%
Tween-20 and 5% non-fat milk for 2 h at 16uC. Serum samples
were serially diluted (2-fold) and 50 ml were added to triplicate
wells and incubated for 1 h at 16uC, and then washed 3 times with
wash buffer (PBS containing 0.05% Tween-20). A rabbit IgG
specific secondary antibody conjugated to HRP (Sigma-Aldrich,
UK), diluted 1:10,000, was added and incubated for 1 h at 16uC.
After three washes with wash buffer, the plate was developed with
a 1-Step 3,3,5,5-tetramethylbenzidine (Pierce Thermo Scientific,
UK) for 20 min in the dark before being stopped with 2 M
H2SO4. Absorbance values were detected at 450 nm using a Bio-
Rad iMark Microplate Reader (Bio-Rad, UK).
The avidity indices of vaccinated sera were measured by its
resistance to 8 M urea in binding to gp140SF162 antigen [49].
Briefly, microwell plates were prepared and blocked as described
above. Serum samples were diluted to give an OD450 nm readout
between 1.0 and 1.5 in endpoint ELISA and were added to two
sets of triplicate wells to incubate for 1 h at 16uC. The wells were
then washed three times with either PBS-Tween or 8 M urea in
PBS-Tween, before incubating with an anti-rabbit secondary
antibody. The plates were washed and developed with TMB as
described above. The avidity index was calculated as the
percentage of average urea treated OD450 nm/average PBS-Tween
OD450 nm. Antisera with index values .50% were designated high
avidity, 30–50% were designated intermediate avidity and ,30%
were designated low avidity.
Real-time neutralizing epitope competition assay
Galanthus nivalis lectin (GNA) was coated at 100 ng/well onto
microwell plates in PBS buffer at 4uC overnight. The microwell
plates were blocked with 2% BSA for 2 h, before gp140SF162
(100 ng/well) was added in triplicate and incubated for 2 h at
16uC. The microplate was washed 3 times with wash buffer
(25 mM Tris-HCl pH 7.8 containing 1% Triton X-100). To
determine the approximate epitopes that the polyclonal sera were
raised to, antisera from vaccinated animals were diluted according
to their endpoint titer to approximately 16105 IgG to compete
with Eu3+-labeled mAbs (100 ng/well) for binding to antigens.
Unbound antisera and mAbs were removed by 6 washes.
Enhancement solution (Perkin Elmer, UK) was added and
incubated for 20 min and the RLU620 nm was measured in a
Envision luminometer (Perkin Elmer, UK). Avidity of the antisera
to the epitopes was determined by reduction in the Eu3+
luminescence intensity of the specific mAb that the serum was
competing with. The 2F5 and 4E10 mAbs were purchased from
Polymun (Vienna, Austria) and other mAbs were kindly provided
upon request (see Acknowledgements).
Neutralization assay
The TZM-bl assay was carried out using a standard protocol
with molecularly cloned pseudoviruses [50]. Briefly, pseudovirus
was incubated with serially diluted rabbit antisera for 1 h at 37uC
before being placed into wells of 96-well plates seeded with TZM-
bl cells. After 48 h incubation at 37uC, the cells were lysed and
luciferase signal in the lysate was developed with Britelite Plus
substrate (1:1 v/v; Perkin Elmer) and read in a luminometer.
Statistical analysis
Comparison of log transformed binding and avidity data
between groups was tested using a one way ANOVA, with a
correction for multiple comparisons between groups conducted
using Tukey’s Honestly Significant Differences. Comparison of
log-transformed neutralization titers between groups was per-
formed using a linear mixed effects model, fitted using a Bayesian
Markov Chain Monte Carlo approach. Markov chains were run
for 110,000 iterations, with a burnin of 10,000 steps, and the
resulting chain was thinned to provide 1,000 samples of parameter
values.
Results
Conformation and antigenicity of gp140 in adjuvant
formulations
To examine if the adjuvants modified antigen conformation,
gp140SF162 was formulated in a single adjuvant or a combination
of adjuvants described in the immunization protocol in Materials
and Methods. The samples were extracted and analyzed for
conformational changes and antigenicity by gel electrophoresis
and antibody binding ELISA.
When gp140SF162 was formulated in FCA or FIA, there was
unavoidable and substantial spillage of the samples from the
wells during loading, particularly for the former. To extract only
the aqueous gp140 from the mineral oil, samples were
centrifuged at high speed and the oil phase was removed.
A New Potent Adjuvant Combination
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However, a smearing separation was still observed in both
reduced and non-reduced, as well as BN-PAGE gels for these
two samples, making interpretation difficult (data not shown).
We observed no biophysical differences with any of the other
adjuvants, including MF59, in either reducing or non-reducing
gels, compared to the unadjuvanted gp140 (Figures 1a & 1b).
Similarly, no differences were observed when samples were
assayed by BN-PAGE (Figure 1c).
To further analyze whether gp140SF162 underwent conforma-
tion changes that could affect its antigenicity in the presence of
adjuvants, we assayed for binding of a panel of mAbs to the
antigen by ELISA. The aqueous glycoprotein was separated from
Figure 1. gp140SF162 conformation upon formulation with adjuvant. The gp140SF162 glycoprotein was formulated with or without adjuvants
and assayed on PAGE gel for conformation. (a) Regardless of presence or absence of adjuvants, a single band at 140 kDa was observed in the reduced
gel. (b) Similar observation was made in the non-reduced gel, where all the samples showed two bands at 140 kDa and 280 kDa, representing the
non-crosslinked and disulfide crosslinked gp140 trimers, respectively. (c) A BN-PAGE gel was used to examine the native conformation of gp140 in the
presence of adjuvants. None of the adjuvants appear to affect the structure of gp140.
doi:10.1371/journal.pone.0035083.g001
Figure 2. Monoclonal antibody binding to gp140SF162 in the presence of adjuvant. The antigenicity of gp140SF162 in the presence of
adjuvants was measured by mAb binding. A panel of 12 different mAbs, representing different epitope domains of the Env, was used. The signal of
mAb binding to the adjuvant-formulated gp140SF162 was calculated relative to the signal measured in the unadjuvanted sample, which is assigned to
have the value of 1. The data is color coded: Yellow represents no difference in mAb binding, or no change of antigenicity as compared to the
unadjuvanted sample and light blue represents up to 3-fold decrease of mAb binding (or antigenicity). Both FIA and MF59 adjuvants appeared to
have little effect on antigenicity, as mAb binding was very similar to the unadjuvanted sample. On the other hand, decreased mAb bindings were
detected in the presence of both of the Carbopols.
doi:10.1371/journal.pone.0035083.g002
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the oil phase from samples containing FCA, FIA or MF59. The
amount of gp140SF162 extracted was quantified and normalized
before coating for ELISA. There was significant loss in mAb
binding in the presence of FCA (data not shown). We suspected
this was due to the high viscosity and hydrophobicity of the
residual mineral oil, which either compromised gp140 binding to
the plate, or heavily masked most of the epitopes and prevent mAb
from accessing them. On the contrary, in the presence of FIA,
which is substantially less viscous, we observed no change in
antigenicity of the extracted gp140 as compared to the
unadjuvanted sample (Figure 2). MF59, the other oil-in-water
emulsion that also has lower viscosity than FCA, showed no
significant changes in gp140 antigenicity as well.
In contrast to the oil-in-water emulsions, gp140SF162 could not
be separated from the Carbopol polymers since both the antigen
and the adjuvants were in aqueous phase. Formulation with
Carbopol-971P alone, or in a mixture with MF59, did not appear
to interfere binding of b12 (CD4bs) or HGN194 (V3 loop), while
modest reduction was observed with other mAbs targeting the
same or other antigenic sites (Figure 2). Similar result was also
demonstrated in a recent study, where mAbs b12 and CD4IgG2
showed indistinguishable level of binding to both native and
Carbopol-971P formulated gp140, while binding of 17b (CD4i)
and F425-B4e8 (V3 loop) was significantly compromised [45].
Since Carbopol is polyanionic, its interaction with the positively
charged side chains of gp140 might induce partial masking and
prohibit mAb binding to its epitope. Nevertheless, further
investigation will be required to study the molecular interaction
between the carbomers and the antigen for an accurate
interpretation.
Combination of Carbopol-971P and MF59 elicited
binding titers comparable to Freund’s adjuvants
Twelve groups of 6 rabbits each were immunized 3 times with
gp140SF162 with different adjuvant regimens (Figure S1). Minor
and transient swelling with reddening at the injection site were
observed in rabbits that received FCA/FIA, which was resolved
within days. No local or systemic reactogenicity was observed in
rabbits that received other adjuvant formulations.
Serum antigen-specific IgG was measured by ELISA at the
terminal bleed, 4 weeks after the 3rd immunization (Figure 3).
Rabbits immunized without adjuvant (group 12) were used as our
low-end benchmark. These animals developed a relatively high
mean titer (6.46105) after three immunizations over the course of
16 weeks, despite no adjuvant being used. FCA/FIA adjuvants
were used as the high-end benchmark, and as expected, groups 1
and 2 had the highest binding IgG titers among all groups
(mean=6.2–6.56106, p,0.05). Although animals in group 1
received 3-fold more gp140SF162 immunogen than those in group
2, there was no significant difference in the mean binding titers,
suggesting that increasing the quantity of antigen does not offer
additional benefits in the presence of a potent adjuvant. Among all
Figure 3. Endpoint IgG binding titer. The antigen-specific IgG titer
was measured by ELISA. Antiserum (terminal time point) was serially
diluted (2-fold) and the endpoint titer was defined as the last dilution
that gave a positive signal (.3-fold signal of the prebleeds). Animals
that received the FCA/FIA (groups 1 and 2) or combination of Carbopol-
971P and MF59 have significantly higher endpoint IgG titers than others
(p,0.05).
doi:10.1371/journal.pone.0035083.g003
Figure 4. Relative avidity index. Avidity of the antiserum was
measured by its ability to remain in binding with gp140SF162 in the
presence of 8 M Urea. All samples were found to have relative high
avidity, defined as .50% IgG binding in the presence of 8 M Urea, as
compared to the no Urea control. Compared to the unadjuvanted
group (no. 12), antisera from animals vaccinated with adjuvants have
significantly higher RAI (p,0.05).
doi:10.1371/journal.pone.0035083.g004
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other adjuvanted groups, only those that were immunized with the
combination of Carbopol-971P and MF59 (group 10) elicited titers
comparable to the FCA/FIA groups (mean= 5.86106, p = 1.00).
When used individually, the titers elicited by MF59 or Carbopol-
971P were 7- to 8-fold lower than the combination group or the
FCA/FIA groups (p,0.001). Sequential immunization of Carbo-
pol-971P followed by MF59 (group 6) or in reverse order (group 8)
also resulted in titers similar to those of the single adjuvant
protocols, indicating that concomitant use of both adjuvants was
needed to enhance antibody titers. In addition, the high antibody
titer induced by the combination group was very specific to the
Carbopol-971P formulation, as the mean titer of those immunized
with combination of Carbopol-974P and MF59 (group 11) was 6-
fold lower in comparison (mean= 9.16105, p,0.005). Individu-
ally, Carbopol-971P appeared to be slightly more active and
elicited higher binding titers of antibodies than Carbopol-974P
(means = 7.246105 and 6.456105, respectively), but overall
differences were not significant.
Adjuvant increased antibody avidity
To estimate antibody affinity maturation, avidity of the antisera
was measured by the 8 M urea displacement method as described
previously [49]. Although all antisera tested have high relative
avidity indices (RAI), defined as .50% residual binding, the mean
RAI was significantly lower in those immunized without adjuvant
(58.5%, p,0.05; Figure 4). The oil-in-water emulsion adjuvants,
such as FCA/FIA and MF59, elicited antibodies with higher RAI,
ranging from 71–82%, whether they were used alone or in
combination with Carbopols. Comparing the two carbomers,
antisera from rabbits immunized with Carbopol-971P had
modestly higher avidity than those immunized with Carbopol-
974P (mean= 74.0% and 66.7%, respectively; Figure 4), although
the difference is not significant between the two groups. Again, as
observed with IgG binding titer, increasing the immunogen dosage
did not have any effect on the avidity, as the polyclonal antisera
from groups 1 and 2 were found to have no significant differences
in their RAI (mean= 76.5% and 76.9%, respectively; Figure 4).
Epitope specificity of the antibodies varied depending on
the adjuvants used
To investigate if antibodies elicited by different adjuvants were
qualitatively distinct in the epitopes that they targeted, the
polyclonal antisera were tested for their ability to compete with
a panel of well-characterized mAbs in binding to gp140SF162. Two
mAbs targeting each distinct antigenic site were used; these
included b12 and VRC01 (CD4bs), 3019 and HGN194 (V3 loop),
17b and E51 (CD4i) and 2F5 and 4E10 (MPER). Antisera were
normalized for endpoint IgG titers, such that similar amounts of
polyclonal antibodies were used to compete each mAb. The
comprehensive results are shown in Figure S2.
Across all groups, it appeared that most of the antibodies elicited
were directed against the CD4bs and the CD4i regions of Env, as
the antisera could out-compete up to 50% of the respective mAbs
(Figure 5). Antisera from animals immunized with the combina-
tion of Carbopol-971P and MF59 (group 10) displayed the
strongest activities to both CD4bs and CD4i, as they could
potently out-compete an average of 80% of the four mAbs tested
(shown as 20% residual mAb binding; Figure 6). To our surprise,
binding activity to the V3 loop was only weakly detectable in most
of the antisera, except those immunized with FCA/FIA (groups 1
and 2) or the combination of Carbopol-971P and MF59 (group
10), where the polyclonal antibodies modestly to potently out-
competed both 3019 and HGN194 mAbs (Figure 6). Similarly,
serum antibody binding to the MPER was either completely
absent or only weakly detected. While animals immunized with
FCA/FIA or combination of Carbopol-971P and MF59 (groups
1&2 and 10, respectively) competed with 2F5 and 4E10 binding to
a modest degree, antisera from other groups, at best, only weakly
out-competed 4E10 and showed limited, if any, competition to
2F5 (Figure 6).
Neutralizing antibody responses
To examine whether different adjuvant formulations had any
effect on neutralization breadth and depth, rabbit antisera were
assessed against a panel of tier 1 pseudoviruses using the standard
TZM-bl assay (comprehensive results shown in Figure S3). Among
animals immunized with either a single adjuvant or different
adjuvants in sequential order, the neutralization titers against the
autologous SF162.LS virus were the highest in animals immunized
with FCA/FIA (groups 1 and 2) with mean group titers of 4,663 to
4,178, respectively (Figure 7). Although the neutralization titer was
slightly higher in group 1 than group 2, the former of which
received 3 times more antigen, the difference in titer was not
significant. When formulated together, this mixture of Carbopol-
971P and MF59 (group 10) was found to be highly immune
stimulating, and elicited neutralizing titers higher than the FCA/
FIA groups against SF162.LS (mean= 4,776; Figure 7). By
contrast, the titers were at least 2-fold lower when MF59 (group
3) or Carbopol-971P (group 4) was used alone (mean= 885 and
2,175, respectively, p,0.05; Figure 7). The same effect was
observed when the antisera were assayed with other pseudoviruses,
in which the combination of Carbopol-971P and MF59 elicited
the highest neutralization titers across all groups and against all
pseudoviruses but BaL.26 (Figure 7). On the other hand,
sequential immunization of Carbopol-971P followed by MF59
Figure 5. Epitope specificity across all antisera by mAb
competition. Across all samples, the polyclonal antibody responses
appeared be mostly CD4bs and CD4i driven, as the antisera could
efficiently out-competed mAbs against these two regions (b12 and
VRC01 for CD4bs and 17b and E51 for CD4i). Modest to little activities
against the V3 loop or the MPER were detected.
doi:10.1371/journal.pone.0035083.g005
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(group 6), or vice versa (group 8), did not have any additive or
synergistic effect and the overall neutralization titers were either
similar or lower than using either Carbopol-971P or MF59 alone
(p.0.5; Figure 7). The increase in titers was specific for the 971P
formulation of Carbopol, as combining Carbopol-974P and MF59
(group 11) resulted in significantly lower titers against all viruses
tested (p,0.05). This observation might in part be due to the fact
that Carbopol-974P (group 5) was less immunogenic than
Carbopol-971P and elicited lower nAb titers on its own
(Figure 7). Of note, even in the absence of adjuvant (group 17)
the antigen was capable of eliciting low titer of nAbs against the
readily neutralized tier 1A pseudoviruses, but the response was
almost completely absent against the more neutralization resistant
tier 1B viruses (Figure 7 and Figure S3).
Discussion
An efficacious preventive vaccine should be one capable of
inducing protective and systemic T-helper responses [51]. For
HIV-1, the Env is the only antigenic determinant for nAb
responses. However, recombinant gp140, peptide mimetics,
structural scaffolds and other rationally designed immunogens
have, thus far, failed to elicit antibodies that are broadly
neutralizing with high titer and prolonged duration that have
been observed in some HIV-1 patients [52]. To compensate for
the poor immunogenicity of these subunit antigens, adjuvant has
often been used to supplement immunogens. Although the precise
mechanism of many adjuvants remains poorly understood,
adjuvants generally act in one or more of the following ways to
enhance immune responses [53,54,55]: (1) they function as a depot
to prolong antigen release and presentation; (2) they act as a
delivery vehicle to promote antigen uptake and presentation by
antigen-presenting cells (APCs) and enhance subsequent traffick-
ing to the lymph nodes; and (3) they activate innate immune
signaling pathways (e.g. TLRs) and/or stimulate the release of pro-
inflammatory cytokines.
Here, we have compared a panel of different adjuvants
including MF59, Carbopol-971P and 974P, against FCA/FIA,
for their ability to enhance humoral responses. Oil-in-water
emulsions, such as FCA/FIA or other modified formulations, are
known for potent adjuvant activities because they possess both
depot forming and immunostimulatory properties [53,55]. Indeed,
animals that were immunized with gp140 in FCA/FIA adjuvant
elicited high titers of nAb, particularly against the autologous
SF162.LS virus (Figure 7 and Figure S3). The potent FCA/FIA
adjuvant also displayed antigen-sparing properties, in which it was
Figure 6. Antisera competition to different mAbs. Antiserum was used to compete with Eu-labeled mAbs specific for different antigenic
domains of Env. The fluorescent signal of Europium is proportional to residual mAb binding, relative to the prebleed controls. A decrease in residual
mAb binding indicated an increase in specificity of the antiserum for the epitope site. Both the FCA/FIA (groups 1&2) and the combination of
Carbopol-971P and MF59 (group 10) displayed potent activities towards both CD4bs and CD4i and modest activities towards the V3 loop and MPER.
By contrast, antisera from animals vaccinated with other adjuvants displayed only modest activities to CD4bs and CD4i and little, if any, towards V3
and MPER.
doi:10.1371/journal.pone.0035083.g006
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unnecessary to increase the antigen dosage in achieving the same
degree of immune response (group 1 vs. group 2; Figure 7 and
Figure S3). Despite possessing superior immunogenicity, oil-in-
water emulsions can also be highly toxic and cause severe local
and systemic adverse effects to vaccinees and cannot easily be used
in prophylactic vaccines [20,21,22,23]. The only emulsion
adjuvant that has been approved for human use is MF59. While
MF59 showed superior humoral responses over the classical alum
adjuvants in a previous study with HBV antigen, it only modestly
increased the antibody titers in the elderly, but not young adults, in
the context of influenza vaccine [56]. In our hands, MF59
promoted a 2-fold increase in nAb titers, compared to unadju-
vanted immunization with gp140SF162 (Figure 7 and Figure S3).
However, nAb responses elicited by MF59 were up to 4-fold lower
than using FCA/FIA, suggesting that reduction in reactogenicity
also compromised adjuvanticity.
Due to safety concerns and existing body of pre-clinical and
clinical data supporting MF59’s use in its present composition
[57], increasing the amount of active ingredient (i.e. Squalene) in
MF59 may not a feasible option for enhancing its adjuvanticity.
Since MF59 is an immunopotentiating adjuvant that elicits a Th2-
type immune bias [27,58], our strategy was to increase the
dimension of adjuvant activity by including another adjuvant with
both depot-forming ability and potent Th1-immune activating
properties. Polymers such as Carbopols have long been used as
controlled release agents in pharmaceuticals [38,39], and more
recently, as adjuvants in veterinary vaccines [40,41,42,43,59].
Among the two polymers in this study, Carbopol-971P contains
fewer crosslinking sites and forms a flexible ‘‘fishnet’’ structure
with little interstitial space between particles; as a result, it has a
slower substance release mechanism [46,47]. By contrast,
Carbopol-974P is highly crosslinked into a ‘‘fuzzball’’ structure
and is less efficient in controlling substance release [46,47]. This
difference in their structural flexibility and controlled release
ability might affect the extent of the depot formation at the
injection site, and thereby accounted for the different adjuvant
activity observed. Individually, Carbopol-971P appeared to be
more stimulatory than its 974P counterpart and elicited higher
nAb titers (Figure 7 and Figure S3). When combined with MF59,
Carbopol-974P offered little advantage over using MF59 alone.
However, a combination of Carbopol-971P and MF59 showed
superior potency over all other adjuvants, including FCA/FIA and
Figure 7. 50% Neutralization titer of individual pseudovirus between groups. For single adjuvant, animals vaccinated with FCA/FIA
(groups 1 and 2) have the highest titers against the tier 1A viruses, and low titers against tier 1B. Sequential immunization with different prime-boost
combination of Carbopol-971P/974P and MF59 (groups 6–9) performed no better than using FCA/FIA or MF59 alone. By contrast, the combination of
Carbopol-971P and MF59 (group 10) conferred significantly higher neutralization titers over all others (p,0.05), particularly against the tier 1B viruses
DJ263.8 and SS1196.1.
doi:10.1371/journal.pone.0035083.g007
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had the highest nAb titers against 5/6 viruses tested (Figure 7 and
Figure S3).
Since the immune pathway mediated by MF59 has not been
fully characterized and that of Carbopols was poorly understood,
substantial investigations are required to understand the mecha-
nism behind the potent adjuvanticity of the Carbopol-971P and
MF59 combination. Nevertheless, we speculate that the effect was
due to simultaneous and synergic immunostimulation, as MF59
and Carbopol can each account for different types of immune
response. In general, MF59 stimulates both Th1 and Th2
responses. It was shown to enhance differentiation of monocytes
into DCs [29], promote local recruitment of monocytes,
granulocytes and DCs [30], increase antigen uptake [28,29] and
facilitate antigen transport to the draining lymph nodes [30]. On
the other hand, Carbopols have been used as antigen delivery
vehicles and is associated to B-cell activation [60]. The anionic
polymer also been shown to induce high titers of both Th1 and
Th2 cytokines and mediate a Th1 isotype-switched antibody
response [44]. We postulate that the difference in adjuvanticity
between Carbopol-971P and 974P was due to greater structural
flexibility and the slow release mechanism of the former, which
can better prolong gp140SF162 antigen exposure to APCs, but also
extend the duration in which MF59 stimulates and recruites local
APCs for antigen uptake, thereby synergistically enhancing the
humoral responses.
While the combination of Carbopol-971P and MF59 could
induce significant increase in antibody response, sequential
immunization with Carbopols followed by MF59 or vice versa
failed to improve nAb titers over using MF59 or Carbopols alone
(groups 6–9; Figure 7 and Figure S3). This observation leads to the
speculation that if one or all of the adjuvants used in sequential
immunization is stimulatory on its own with a distinct mechanism,
then a prime-boost protocol may not provide enough stimuli to
sufficiently mediate each response for a synergic effect, particularly
if the immunizations were administered over a short time course
like the one here.
Although the use of adjuvants, particularly those with limited
immunogenicity, does not necessarily increase the overall antigen-
specific IgG titers (Figure 3), they might at least facilitate the
generation of high avidity antibodies (Figure 4), which are
suggested to correlate with protection in vivo [1,2,3]. In addition,
the more potent adjuvants, such as FCA/FIA, MF59 and the
combination Carbopol-971P and MF59 enhanced nAb titers and
magnified the responses to the V3 loops and MPER that were only
weakly detectable with other adjuvants (Figure 6 and Figure S2).
Finally, the significant increase in nAb titers elicited by the
combination of Carbopol-971P and MF59 is universal, as
subsequent immunization studies with different antigens in
different species also raised superior nAb titers over other adjuvant
protocols (unpublished data and [45]). Taken together, future
studies will be undertaken with the Carbopol-971P and MF59
combination formulated with modified HIV-1 Env antigens, in
effort to elicit nAbs targeting the most desired nAb epitopes.
Supporting Information
Table S1 Sample adjuvant formulation. An example on
formulation with different adjuvant(s) is detailed here. In this study,
the gp140SF162 glycoprotein was concentrated to 1 mg/ml, such that
25 mg of antigen was equivalent to 25 ml. The volume of adjuvants
used should be adjusted according to the volume of the antigen,
depending on its concentration, in other cases. The final concentra-
tion and volume of each adjuvant, as well as the antigen-adjuvant
mixture, was kept identical in all groups to allow direct comparison.
(TIF)
Figure S1 Immunization protocol. Twelve groups of 6
rabbits each were immunized with HIV-1 gp140SF162 at week 0, 4
and 12 with the adjuvants listed. Animals in group 1 received
75 mg of Env glycoprotein per injection, while all others received
25 mg of the same antigen. An unadjuvanted control group
(no. 12) was included for baseline measure.
(TIF)
Figure S2 Summary of mAb competition with antisera.
Summary of antisera competition with different mAbs is shown.
Each treatment group consists of 6 rabbits (Rb), except for group 1
in which Rb5 died before the completion of the study. Results are
color coded: Black represents less than 15% of residual mAb
binding (or .85% displacement of mAb by the antiserum, relative
to the prebleed); red is 16–30% residual mAb binding; orange is
31–50% and yellow is 51–75%. If the antiserum failed to out-
compete at least 25% of the mAb (.75% residual mAb binding),
they are considered negative and the value is uncolored.
(TIF)
Figure S3 Neutralization titer by TZM-bl assay. The
50% neutralization titer against a panel of tier 1A and 1B
pseudovirus was determined by the TZM-bl assay. Each treatment
group consists of 6 rabbits (Rb), except for group 1 in which Rb5
died before the completion of the study. The IC50 titer was
considered true positive (colored) if it is at least 3-fold higher than
the corresponding pre-bleeds (week 22) sample.
(TIF)
Acknowledgments
We would like to thank Barbara Blacklaws for critically reviewing the
manuscript. We would also like to thank J. Mascola and G. Nabel of the
VRC for VRC01 antibody, D. Burton for b12 antibody, J. Robinson for
17B and E51 antibodies, S. Zolla-Pazner for 3019 antbody and D. Corti
for the HGN194 antibody. We would also like to thank M. Vazquez for
help with the animal work.
Author Contributions
Conceived and designed the experiments: RPJL IKS QS SWB JLH.
Performed the experiments: RPJL PT FW DJS AKD. Analyzed the data:
RPJL MSS SDWF CCL DCM. Contributed reagents/materials/analysis
tools: MSS SDWF CCL DCM AKD IKS QS SWB. Wrote the paper:
RPJL JLH.
References
1. Devash Y, Calvelli TA, Wood DG, Reagan KJ, Rubinstein A (1990) Vertical
transmission of human immunodeficiency virus is correlated with the absence of
high-affinity/avidity maternal antibodies to the gp120 principal neutralizing
domain. Proc Natl Acad Sci U S A 87: 3445–3449.
2. Binley JM, Arshad H, Fouts TR, Moore JP (1997) An investigation of the high-
avidity antibody response to glycoprotein 120 of human immunodeficiency virus
type 1. AIDS Res Hum Retroviruses 13: 1007–1015.
3. Zhao J, Lai L, Amara RR, Montefiori DC, Villinger F, et al. (2009) Preclinical
studies of human immunodeficiency virus/AIDS vaccines: inverse correlation
between avidity of anti-Env antibodies and peak postchallenge viremia. J Virol
83: 4102–4111.
4. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, et al. (2010)
Polyreactivity increases the apparent affinity of anti-HIV antibodies by
heteroligation. Nature 467: 591–595.
5. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad
and potent neutralizing antibodies from an African donor reveal a new HIV-1
vaccine target. Science 326: 285–289.
6. Huber M, Le KM, Doores KJ, Fulton Z, Stanfield RL, et al. (2010) Very few
substitutions in a germ line antibody are required to initiate significant domain
exchange. J Virol 84: 10700–10707.
7. Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P, et al. (2009) Germline-like
predecessors of broadly neutralizing antibodies lack measurable binding to HIV-
A New Potent Adjuvant Combination
PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e35083
1 envelope glycoproteins: implications for evasion of immune responses and
design of vaccine immunogens. Biochem Biophys Res Commun 390: 404–409.
8. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, et al. (2010) Analysis of
memory B cell responses and isolation of novel monoclonal antibodies with
neutralizing breadth from HIV-1-infected individuals. PLoS One 5: e8805.
9. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, et al. (2010) Rational design
of envelope identifies broadly neutralizing human monoclonal antibodies to
HIV-1. Science 329: 856–861.
10. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, et al. (2011) Focused evolution of
HIV-1 neutralizing antibodies revealed by structures and deep sequencing.
Science 333: 1593–1602.
11. Halperin SA, Dobson S, McNeil S, Langley JM, Smith B, et al. (2006)
Comparison of the safety and immunogenicity of hepatitis B virus surface
antigen co-administered with an immunostimulatory phosphorothioate oligo-
nucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine
24: 20–26.
12. Boyle J, Eastman D, Millar C, Camuglia S, Cox J, et al. (2007) The utility of
ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring
antibody responses. Vaccine 25: 2541–2544.
13. Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, et al. (2007) Vaccination
with recombinant fusion proteins incorporating Toll-like receptor ligands
induces rapid cellular and humoral immunity. Vaccine 25: 763–775.
14. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, et al. (2009)
MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic
antibody responses in non-elderly and elderly adults. PLoS One 4: e4384.
15. Galli G, Hancock K, Hoschler K, DeVos J, Praus M, et al. (2009) Fast rise of
broadly cross-reactive antibodies after boosting long-lived human memory B
cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad
Sci U S A 106: 7962–7967.
16. Schwarz TF, Horacek T, Knuf M, Damman HG, Roman F, et al. (2009) Single
dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial
induces strong and broad immune responsiveness to booster vaccination in
adults. Vaccine 27: 6284–6290.
17. O’Hagan DT (2000) Vaccine adjuvants: preparation methods and research
protocols. Totowa, N.J.: Humana. x, 342 p.
18. Miller LH, Saul A, Mahanty S (2005) Revisiting Freund’s incomplete adjuvant
for vaccines in the developing world. Trends Parasitol 21: 412–414.
19. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V (2002) Montanide
ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for
human vaccines. Expert Rev Vaccines 1: 111–118.
20. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, et al. (2008) Phase 1 trial of
malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated
with montanide ISA 51. PLoS One 3: e2636.
21. Genton B, Al-Yaman F, Anders R, Saul A, Brown G, et al. (2000) Safety and
immunogenicity of a three-component blood-stage malaria vaccine in adults
living in an endemic area of Papua New Guinea. Vaccine 18: 2504–2511.
22. Toledo H, Baly A, Castro O, Resik S, Laferte J, et al. (2001) A phase I clinical
trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720
adjuvant in non-HIV-1 infected human volunteers. Vaccine 19: 4328–4336.
23. Graham BS, McElrath MJ, Keefer MC, Rybczyk K, Berger D, et al. (2010)
Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is
immunogenic, but causes sterile abscesses and unacceptable reactogenicity.
PLoS One 5: e11995.
24. Glenny AT (1930) Insoluble Precipitates in Diphtheria and Tetanus Immuni-
zation. Br Med J 2: 244–245.
25. Gregoriadis G, Allison AC, Poste G, North Atlantic Treaty Organization.
Scientific Affairs Division (1989) Immunological adjuvants and vaccines. New
York; London: Plenum. viii, 244 p.
26. Podda A, Del Giudice G (2003) MF59-adjuvanted vaccines: increased
immunogenicity with an optimal safety profile. Expert Rev Vaccines 2: 197–203.
27. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, et al.
(1995) MF59. Design and evaluation of a safe and potent adjuvant for human
vaccines. Pharm Biotechnol 6: 277–296.
28. Dupuis M, Murphy TJ, Higgins D, Ugozzoli M, van Nest G, et al. (1998)
Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell
Immunol 186: 18–27.
29. Seubert A, Monaci E, Pizza M, O’Hagan DT, Wack A (2008) The adjuvants
aluminum hydroxide and MF59 induce monocyte and granulocyte chemoat-
tractants and enhance monocyte differentiation toward dendritic cells.
J Immunol 180: 5402–5412.
30. Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, et al. (2011) Vaccine
adjuvants alum and MF59 induce rapid recruitment of neutrophils and
monocytes that participate in antigen transport to draining lymph nodes.
Vaccine 29: 1812–1823.
31. Traquina P, Morandi M, Contorni M, Van Nest G (1996) MF59 adjuvant
enhances the antibody response to recombinant hepatitis B surface antigen
vaccine in primates. J Infect Dis 174: 1168–1175.
32. Heineman TC, Clements-Mann ML, Poland GA, Jacobson RM, Izu AE, et al.
(1999) A randomized, controlled study in adults of the immunogenicity of a
novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 17: 2769–2778.
33. Pass RF, Duliege AM, Boppana S, Sekulovich R, Percell S, et al. (1999) A
subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B
and a new adjuvant. J Infect Dis 180: 970–975.
34. Langenberg AG, Burke RL, Adair SF, Sekulovich R, Tigges M, et al. (1995) A
recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and
immunogenicity [corrected]. Ann Intern Med 122: 889–898.
35. Kahn JO, Sinangil F, Baenziger J, Murcar N, Wynne D, et al. (1994) Clinical
and immunologic responses to human immunodeficiency virus (HIV) type 1SF2
gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl
tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human
volunteers. J Infect Dis 170: 1288–1291.
36. Nitayaphan S, Khamboonruang C, Sirisophana N, Morgan P, Chiu J, et al.
(2000) A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative
thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research
Institute of Medical Sciences and the Research Institute for Health Sciences.
Vaccine 18: 1448–1455.
37. Cunningham CK, Wara DW, Kang M, Fenton T, Hawkins E, et al. (2001)
Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1)
envelope vaccines in neonates born to HIV-1-infected women. Clin Infect Dis
32: 801–807.
38. Wade A, Weller PJ (1994) Handbook of pharmaceutical excipients. Washington:
American Pharmaceutical Association; London: Pharmaceutical Press. xv,651 p.
39. Blanco-Fuente H, Anguiano-Igea S, Otero-Espinar FJ, Blanco-Mendez J (1996)
In-vitro bioadhesion of carbopol hydrogels. Int J Pharm. pp 169–174.
40. Gualandi GL, Losio NM, Muratori G, Foni E (1988) The ability by different
preparations of porcine parvovirus to enhance humoral immunity in swine and
guinea pigs. Microbiologica 11: 363–369.
41. Mumford JA, Wilson H, Hannant D, Jessett DM (1994) Antigenicity and
immunogenicity of equine influenza vaccines containing a Carbomer adjuvant.
Epidemiol Infect 112: 421–437.
42. Elicker S, Sipos W (2009) The tissue compatibility of different Mycoplasma
hyopneumoniae vaccines is mainly dependent upon their adjuvants. Berl Munch
Tierarztl Wochenschr 122: 348–353.
43. (2010) Suvaxyn M.hyo Suspension for injection for pigs. http://wwwnoah-
compendiumcouk/Pfizer_Limited/documents/S3979html Accessed 2011 Nov 18.
44. Krashias G, Simon AK, Wegmann F, Kok WL, Ho LP, et al. (2010) Potent
adaptive immune responses induced against HIV-1 gp140 and influenza virus
HA by a polyanionic carbomer. Vaccine 28: 2482–2489.
45. Dey AK, Burke B, Sun Y, Hartog K, Heeney JL, et al. (2012) Use of a
polyanionic carbomer, Carbopol971P, in combination with MF59, improves
antibody responses to HIV-1 envelope glycoprotein. Vaccine.
46. Karsa DRE, Stephenson RAE Chemical aspects of drug delivery systems: Royal
Society of Chemistry.
47. Bonacucina G, Martelli S, Palmieri GF (2004) Rheological, mucoadhesive and
release properties of Carbopol gels in hydrophilic cosolvents. Int J Pharm 282:
115–130.
48. Srivastava IK, Stamatatos L, Legg H, Kan E, Fong A, et al. (2002) Purification
and characterization of oligomeric envelope glycoprotein from a primary R5
subtype B human immunodeficiency virus. J Virol 76: 2835–2847.
49. Cole KS, Rowles JL, Jagerski BA, Murphey-Corb M, Unangst T, et al. (1997)
Evolution of envelope-specific antibody responses in monkeys experimentally
infected or immunized with simian immunodeficiency virus and its association
with the development of protective immunity. J Virol 71: 5069–5079.
50. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human
immunodeficiency virus type 1 env clones from acute and early subtype B
infections for standardized assessments of vaccine-elicited neutralizing antibod-
ies. J Virol 79: 10108–10125.
51. Heeney JL (2004) Requirement of diverse T-helper responses elicited by HIV
vaccines: induction of highly targeted humoral and CTL responses. Expert Rev
Vaccines 3: S53–64.
52. Mascola JR, Montefiori DC (2010) The role of antibodies in HIV vaccines.
Annu Rev Immunol 28: 413–444.
53. Gupta RK, Siber GR (1995) Adjuvants for human vaccines–current status,
problems and future prospects. Vaccine 13: 1263–1276.
54. Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: putting innate
immunity to work. Immunity 33: 492–503.
55. Manmohan Singh N (2007) Vaccine adjuvants and delivery systems. Hoboken,
N.J.: Wiley-Interscience; Chichester: John Wiley [distributor]. x, 449 p.
56. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R (2010) New adjuvants for
human vaccines. Curr Opin Immunol 22: 411–416.
57. O’Hagan DT (2007) MF59 is a safe and potent vaccine adjuvant that enhances
protection against influenza virus infection. Expert Rev Vaccines 6: 699–710.
58. Dey AK, Srivastava IK (2011) Novel adjuvants and delivery systems for
enhancing immune responses induced by immunogens. Expert Rev Vaccines 10:
227–251.
59. Opriessnig T, Fenaux M, Thomas P, Hoogland MJ, Rothschild MF, et al. (2006)
Evidence of breed-dependent differences in susceptibility to porcine circovirus
type-2-associated disease and lesions. Vet Pathol 43: 281–293.
60. Cranage MP, Fraser CA, Cope A, McKay PF, Seaman MS, et al. (2011)
Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54
clade C gp140 in Carbopol gel are augmented by systemic priming or boosting
with an adjuvanted formulation. Vaccine 29: 1421–1430.
A New Potent Adjuvant Combination
PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e35083
